A proof-of-concept phase 2, randomized, placebo-controlled, double blind, multicentre clinical trial in 2 parallel groups to evaluate the efficacy and safety of E-52862 for reducing the incidence and severity of oxaliplatin-induced peripheral neuropathy in patients treated for colorectal cancer

Trial Profile

A proof-of-concept phase 2, randomized, placebo-controlled, double blind, multicentre clinical trial in 2 parallel groups to evaluate the efficacy and safety of E-52862 for reducing the incidence and severity of oxaliplatin-induced peripheral neuropathy in patients treated for colorectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs E 52862 (Primary)
  • Indications Peripheral neuropathies
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Laboratorios Dr. Esteve
  • Most Recent Events

    • 30 Sep 2016 Results of this study, presented at the 16th World Congress on Pain.
    • 09 May 2015 Status changed from recruiting to completed, as per European Clinical Trials Database record.
    • 11 Aug 2012 Additional location [Greece] identified as reported by as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top